CAS 231277-92-2

Lapatinib

Descripción:

Lapatinib es un inhibidor de la tirosina quinasa de pequeñas moléculas utilizado principalmente en el tratamiento de ciertos tipos de cáncer de mama, particularmente aquellos que son HER2-positivos. Funciona inhibiendo la actividad del receptor del factor de crecimiento epidérmico (EGFR) y HER2, que están involucrados en la proliferación y supervivencia de las células cancerosas. Lapatinib se administra típicamente por vía oral y a menudo se utiliza en combinación con otras terapias, como la capecitabina, para mejorar su eficacia. El compuesto tiene una fórmula molecular que refleja su estructura compleja, que incluye múltiples anillos aromáticos y grupos funcionales que contribuyen a su actividad farmacológica. Lapatinib se caracteriza por su moderada solubilidad en disolventes orgánicos y su relativamente baja solubilidad en agua, lo que puede influir en su biodisponibilidad. Los efectos secundarios pueden incluir diarrea, erupción cutánea y posibles problemas cardíacos, lo que requiere un monitoreo cuidadoso durante el tratamiento. En general, Lapatinib representa un enfoque terapéutico dirigido en oncología, ejemplificando el cambio hacia la medicina personalizada en el tratamiento del cáncer.

Fórmula: C₂₉H₂₆ClFN₄O₄S

InChI: InChI=1/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)

Clave InChI: InChIKey=BCFGMOOMADDAQU-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C=CC(=C2)C=3OC(CNCCS(C)(=O)=O)=CC3)N=CN1)C4=CC(Cl)=C(OCC5=CC(F)=CC=C5)C=C4

Sinónimos:

• 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-
• 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
• Gd 2016
• Gsk 572016
• Gw 572016
• Gw 572016X
• Lapatinib base
• N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methanesulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
• N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
• N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine
• N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
• N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine
• N-[4-(3-Fluorobenzyloxy)-3-chlorophenyl]-6-[5-[[2-(methylsulfonyl)ethylamino]methyl]furan-2-yl]quinazolin-4-amine
• N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine
• Tycerb
• Tyverb
• Lapatinib

Lapatinib

CAS: 231277-92-2

Fórmula: C₂₉H₂₆ClFN₄O₄S

Pureza: >98.0%(T)(HPLC)

Forma y color: White to Light yellow powder to crystal

Peso molecular: 581.06

Ref: 3B-L0360

N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine

CAS: 231277-92-2

Fórmula: C₂₉H₂₆ClFN₄O₄S

Pureza: 98%

Forma y color: Solid

Peso molecular: 581.0575

Ref: IN-DA0039KT

Lapatinib

CAS: 231277-92-2

Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity.

Fórmula: C₂₉H₂₆ClFN₄O₄S

Pureza: 99.00% - 99.81%

Forma y color: Powder

Peso molecular: 581.06

Ref: TM-T0078

Lapatinib

CAS: 231277-92-2

Fórmula: C₂₉H₂₆ClFN₄O₄S

Pureza: ≥ 99.0%

Forma y color: Pale yellow to yellow powder

Peso molecular: 581.06

Ref: 7W-GP6924

Lapatinib

CAS: 231277-92-2

Lapatinib

Pureza: ≥98%

Peso molecular: 581.06g/mol

Ref: 54-BUP16996

Lapatinib

CAS: 231277-92-2

Fórmula: C₂₉H₂₆ClFN₄O₄S

Forma y color: Yellow Solid

Peso molecular: 581.06

Ref: 4Z-L-251

Lapatinib

CAS: 231277-92-2

Lapatinib

Pureza: 98%

Peso molecular: 581.06g/mol

Ref: 54-PC108772

Lapatinib

Producto controlado

CAS: 231277-92-2

Applications Lapatinib is a selective inhibitor of epidermal growth factor receptor (EGFR) and HER-2 tyrosine kinases. This drug is used to treat breast cancer, especially metastatic breast cancer that has progressed after trastuzumab treatment and other chemotherapy.
References Konecny, G., et al.: Cancer Res., 66, 1630 (2006); Geyer, C., et al.: N. Engl. J. Med., 355, 2733 (2006);

Fórmula: C₂₉H₂₆ClFN₄O₄S

Forma y color: Light Yellow

Peso molecular: 581.06

Ref: TR-L175808

Lapatinib

CAS: 231277-92-2

Inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptor tyrosine kinases. Used for sensitization of HER2-overexpressing cancer cells to radiation as well as chemotherapy to tamoxifen- and trastuzumab-resistant cell lines. The compound blocks signalling via Akt and mitogen-activated protein kinase (MAPK) pathways leading to reduced cell survival. In trastuzumab resistant cancer cells, it inhibits HER2 phosphorylation, prevents receptor ubiquitination and causes accumulation of inactive HER2 dimers on the cell surface.

Fórmula: C₂₉H₂₆ClFN₄O₄S

Pureza: Min. 95%

Forma y color: Slightly Yellow Powder

Peso molecular: 581.06 g/mol

Ref: 3D-FC12433

Lapatinib base - Bio-X ™

CAS: 231277-92-2

Lapatinib is an antineoplastic agent used to treat breast and lung cancer. This drug is also a tyrosine kinase inhibitor and inhibits human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1). Lapatinib has shown to inhibit ERBB-driven tumor cell growth in vitro and in various animal models.

Fórmula: C₂₉H₂₆ClFN₄O₄S

Pureza: Min. 95%

Forma y color: Powder

Peso molecular: 581.06 g/mol

Ref: 3D-BC164610

Lapatinib ditosylate monohydrate

CAS: 231277-92-2

Inhibitor of EGFR (ErbB1) and HER2 (ErbB2) receptor tyrosine kinases. Used for sensitization of HER2-overexpressing cancer cells to radiation as well as chemotherapy to tamoxifen- and trastuzumab-resistant cell lines. The compound blocks signalling via Akt and mitogen-activated protein kinase (MAPK) pathways leading to reduced cell survival. In trastuzumab resistant cancer cells, it inhibits HER2 phosphorylation, prevents receptor ubiquitination and causes accumulation of inactive HER2 dimers on the cell surface.

Fórmula: C₂₉H₂₆ClFN₄O₄S•(C₇H₈O₃S)₂•H₂O

Pureza: Min. 95%

Peso molecular: 943.48 g/mol

Ref: 3D-FL24843